Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Aids.php on line 2
Aids
LE WE PMID CA
Aids11Aids

Abacavir

Abdomen (CT)

Acidosis (Lactate)

AIDCA AID cytidine deaminase

Aids

Alzheimer s disease

Antibodies (Immunochemistry)

Anus (Neoplasm)

APOBEC3G

Apricitabine

Atazanavir

Autoantibodies Anti CCR5

Autophagy

Bevirimate

Bone (BASKET)

Cardiovascular risk

CCR5

CD274 PD L1 B7H1

CNS (Blood brain barrier)

CNS (Imaging)

Cofilin

Cryptococcosis

Death receptor5 DR5

Dendritic cell (Plasmacytoid)

Disaster medicine

EBV Epstein barr virus

eEF1A

Efavirenz

Elvitegravir

Emtricitabine

Enfuvirtide

Equine infectious anemia virus EIAV

ERS UFR (Apoptosis)

Etravirine

ExportinT

Fosamprenavir

GBV C

Hepatitis B

Hepatitis C

Histone deacetylase

HIV1

HIV2

HTLV1

Human herpesvirus7

Human papilloma virus

IDO Indoleamine oxygenase

Immune reconstitution

Immunogenetics (Somatic hypermutation)

Innate immunity

Insomnia

Interferon alpha and preliminary (BASKET)

Intestines (Immunology)

Kidney (Diseases viral HIV HIVAN)

Kidney (Neoplasia RCC)

Laboratory animal (Animal Human chimerism)

LEDGF lens epithelium derived growth factor p75

Leishmaniasis

Lentivirus

Lepra

Leptin

Lipodystrophy

Liver (Fibrosis)

Lopinavir

Lung (Pneumonia BASKET)

Lymphoma (extranodal Primary CNS)

Macrophages

Maraviroc

Metoogravir

Molluscum contagiosum

MRSA

Nanomedicine

Nef

Neonatology

Neuropathy peripheral

Nevirapine

ORL (Neoplasia)

PD1

Penicilliosis marnefei

Postexposition prophylaxis

Psoriasis

Quinolinic acid

Raltegravir

Ritonavir

RNA (MicroRNA)

Simian immunodeficiency virus

T Cell (Exhaustion)

T cell (gammadelta)

T cell (Th17)

Teratogenesis

Tetanus

Thorax (CT)

Thrombotic microangiopathies

Tipranavir

Toxoplasmosis

TRAIL APO2

Tuberculosis

Virologic synapse

Virus (Endocytosis)

Virus (Immune reaction)

Virus (Integration)

Vpr

Vpx

Zidovudine

1987  
1
Dermatological conditions in HIV infection.
[3101788] Br Med J (Clin Res Ed) 294(6563): 29-32 (1987)
1986  
2
The natural history of human T lymphotropic virus-III infection: the cause of AIDS.
[3002536] Br Med J (Clin Res Ed) 292(6512): 5-12 (1986)
2003  
3
Lipodystrophy, insulin resistance, diabetes mellitus, dyslipidemia, and cardiovascular disease in human immunodeficiency virus infection.
[12630645] South Med J 96(2): 180-8; quiz 189 (2003)
2002  
4
Primary human immunodeficiency virus.
[12539999] South Med J 95(11): 1312-7 (2002)
2001  
5
Neurologic abnormalities in human immunodeficiency virus infection.
[11284512] South Med J 94(3): 266-75 (2001)
1999  
6
Manifestations of AIDS in the head and neck.
[10414477] South Med J 92(7): 684-97 (1999)
1997  
7
Psychiatric perspective of pediatric human immunodeficiency virus infection.
[9347811] South Med J 90(10): 1007-16 (1997)
1994  
8
Hypereosinophilic syndrome associated with HIV infection. Military Medical Consortium for Applied Retroviral Research.
[8153785] South Med J 87(4): 525-9 (1994)
1994  
9
HIV and pulmonary hypertension: a review.
[8134859] South Med J 87(3): 357-62 (1994)
1989  
10
Psychiatric manifestations of AIDS spectrum disorders.
[2646732] South Med J 82(3): 352-7 (1989)
1988  
11
Adrenal insufficiency in the acquired immunodeficiency syndrome.
[3059512] South Med J 81(12): 1493-5 (1988)
2009  
12
Molecular Mechanisms of Neurodegenerative Diseases Induced by Human Retroviruses: A Review.
[20352020] Am J Infect Dis 5(3): 231-258 (2009)
2007  
13
Predictors of disease progression in HIV infection: a review.
[17502001] AIDS Res Ther 4(): 11 (2007)
2007  
14
Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options.
[17488505] AIDS Res Ther 4(): 9 (2007)
1997  
15
Pathology of acquired immunodeficiency syndrome.
[9250911] J Korean Med Sci 12(3): 171-84 (1997)
2009  
16
New options in the treatment of lipid disorders in HIV-infected patients.
[19639034] Open AIDS J 3(): 31-7 (2009)
1989  
17
Hematologic abnormalities in patients with the acquired immunodeficiency syndrome. A controlled study and brief review of literature.
[2681494] J Med 20(3-4): 177-92 (1989)
2009  
18
LIPODYSTROPHY SYNDROME IN HIV-INFECTED CHILDREN ON HAART.
[20706598] South Afr J HIV Med 10(4): 76-80 (2009)
2000  
19
Cardiac manifestations of acquired immunodeficiency syndrome.
[10724045] Arch Intern Med 160(5): 602-8 (2000)
1999  
20
Think HIV: why physicians should lower their threshold for HIV testing.
[10510984] Arch Intern Med 159(17): 1994-2000 (1999)
2008  
21
The first postmodern pandemic: 25 years of HIV/ AIDS.
[18205765] J Intern Med 263(3): 218-43 (2008)
1993  
22
Acquired immunodeficiency syndrome--a review and update. History, characteristics of human immunodeficiency virus infection, its replication, biologic factors, and pathogenicity.
[8111489] Arch Fam Med 2(10): 1068-77 (1993)
2001  
23
Cardiovascular manifestations of HIV infection.
[11461981] J R Soc Med 94(8): 384-90 (2001)
1987  
24
Surgeon General's report on acquired immune deficiency syndrome.
[3101112] Public Health Rep 102(1): 1-3 (1987)
1983  
25
The science base underlying research on acquired immune deficiency syndrome.
[6318255] Public Health Rep 98(6): 559-65 (1983)
1991  
26
Do physicians have an ethical obligation to care for patients with AIDS?
[1788990] Yale J Biol Med 64(3): 207-46 (1991)
1987  
27
Neurology of AIDS virus infection: a clinical classification.
[2829450] Yale J Biol Med 60(6): 537-43 (1987)
1982  
28
The Acquired Immunodeficiency Syndrome: current status.
[6134399] Yale J Biol Med 55(5-6): 443-52 (1982)
2003  
29
Tumor necrosis factor-alpha at the crossroads of neuronal life and death during HIV-associated dementia.
[12911614] J Neurochem 86(5): 1057-71 (2003)
2007  
30
HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse.
[17173547] J Neurochem 100(3): 567-86 (2007)
2005  
31
Rodent model systems for studies of HIV-1 associated dementia.
[16260388] Neurotox Res 8(1-2): 91-106 (2005)
2005  
32
The AIDS dementia complex: clinical and basic neuroscience with implications for novel molecular therapies.
[16260383] Neurotox Res 8(1-2): 3-24 (2005)
2005  
33
Involvement of quinolinic acid in AIDS dementia complex.
[15639803] Neurotox Res 7(1-2): 103-23 (2005)
2004  
34
Neuroprotective strategies for HIV-1 associated dementia.
[15639783] Neurotox Res 6(7-8): 503-21 (2004)
1992  
35
Pain syndromes in HIV infection.
[1394763] Can J Anaesth 39(7): 724-30 (1992)
2001  
36
The expanding role of the cardiologist in the care of HIV infected patients.
[11559669] Heart 86(4): 365-7 (2001)
2006  
37
Antiretroviral therapy 2006: pharmacology, applications, and special situations.
[16833010] Arch Pharm Res 29(6): 431-58 (2006)
2006  
38
Successful HIV treatment: lessons learned.
[16984222] J Manag Care Pharm 12(7 Suppl B): S6-11 (2006)
2010  
39
CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on.
[20413825] Antivir Chem Chemother 20(5): 179-92 (2010)
2009  
40
Elvitegravir: a new HIV integrase inhibitor.
[19843978] Antivir Chem Chemother 20(2): 79-85 (2009)
2009  
41
Antiretroviral therapy in macrophages: implication for HIV eradication.
[19843977] Antivir Chem Chemother 20(2): 63-78 (2009)
2009  
42
Current peptide HIV type-1 fusion inhibitors.
[19794228] Antivir Chem Chemother 20(1): 1-18 (2009)
2009  
43
RNA-interference-based gene therapy approaches to HIV type-1 treatment: tackling the hurdles from bench to bedside.
[19641231] Antivir Chem Chemother 19(6): 221-33 (2009)
2009  
44
Novel compounds for the treatment of HIV type-1 infection.
[19483267] Antivir Chem Chemother 19(5): 189-200 (2009)
2009  
45
HIV type-1 latency: targeted induction of proviral reservoirs.
[19483266] Antivir Chem Chemother 19(5): 177-87 (2009)
2008  
46
Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
[19024627] Antivir Chem Chemother 19(3): 107-13 (2008)
2007  
47
Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.
[17542150] Antivir Chem Chemother 18(2): 61-70 (2007)
2005  
48
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
[16329283] Antivir Chem Chemother 16(6): 339-54 (2005)
2004  
49
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
[15266894] Antivir Chem Chemother 15(3): 121-34 (2004)
2004  
50
Gene silencing of HIV-1 by RNA interference.
[15185724] Antivir Chem Chemother 15(2): 57-65 (2004)
2001  
51
Cytokines and HIV-1: interactions and clinical implications.
[12959322] Antivir Chem Chemother 12(3): 133-50 (2001)
2001  
52
Structural studies of chemokines that inhibit HIV-1 entry.
[11594687] Antivir Chem Chemother 12 Suppl 1(-): 43-9 (2001)
1999  
53
Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom.
[10628805] Antivir Chem Chemother 10(6): 285-314 (1999)
1999  
54
Human immunodeficiency virus type 1 entry and chemokine receptors: a new therapeutic target.
[10335399] Antivir Chem Chemother 10(2): 53-62 (1999)
1999  
55
Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy.
[10079874] Antivir Chem Chemother 10(1): 1-14 (1999)
2010  
56
Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
[20834093] Antivir Ther 15(6): 803-16 (2010)
2010  
57
Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
[20587860] Antivir Ther 15(4): 677-80 (2010)
2009  
58
Hypophosphataemia: an easy strategy for diagnosis and treatment in HIV patients.
[19578233] Antivir Ther 14(4): 481-8 (2009)
2007  
59
Late presentation of HIV-infected individuals.
[17926639] Antivir Ther 12(6): 841-51 (2007)
2005  
60
Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
[15751761] Antivir Ther 10(1): 29-40 (2005)
2004  
61
Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
[15134178] Antivir Ther 9(2): 161-77 (2004)
2003  
62
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
[14760883] Antivir Ther 8(6): 489-506 (2003)
2003  
63
Mitochondria and lipodystrophy: where are we now?
[14518694] Antivir Ther 8(4): 261-3 (2003)
2001  
64
Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
[11808750] Antivir Ther 6(3): 145-60 (2001)
2001  
65
Antiretroviral therapy and the lipodystrophy syndrome.
[11417766] Antivir Ther 6(1): 9-20 (2001)
1999  
66
Pharmacology of antiretroviral drugs.
[16021869] Antivir Ther 4 Suppl 3(-): 29-41 (1999)
2008  
67
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults.
[18257771] HIV Med 9(2): 82-8 (2008)
2008  
68
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.
[18257770] HIV Med 9(2): 72-81 (2008)
2008  
69
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults.
[18257769] HIV Med 9(2): 65-71 (2008)
2007  
70
The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review.
[17661840] HIV Med 8(6): 325-34 (2007)
2007  
71
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
[17305925] HIV Med 8(1): 1-7 (2007)
2006  
72
Counteracting muscle wasting in HIV-infected individuals.
[16945075] HIV Med 7(5): 299-310 (2006)
2005  
73
Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission of HIV.
[16033339] HIV Med 6 Suppl 2(): 107-48 (2005)
2005  
74
Guidelines for liver transplantation in patients with HIV infection (2005).
[16011540] HIV Med 6 Suppl 2(): 149-53 (2005)
2005  
75
BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005).
[16011539] HIV Med 6 Suppl 2(): 96-106 (2005)
2005  
76
BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection (2005).
[16011538] HIV Med 6 Suppl 2(): 84-95 (2005)
2005  
77
BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.
[16011537] HIV Med 6 Suppl 2(): 62-83 (2005)
2005  
78
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).
[16011536] HIV Med 6 Suppl 2(): 1-61 (2005)
2005  
79
2005  
80
Impact of highly active antiretroviral therapy on organ-specific manifestations of HIV-1 infection.
[15807712] HIV Med 6(2): 66-78 (2005)
2004  
81
Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE) therapy in Thailand.
[15369506] HIV Med 5(5): 317-25 (2004)
2004  
82
PENTA guidelines for the use of antiretroviral therapy, 2004.
[15239717] HIV Med 5 Suppl 2(): 61-86 (2004)
2001  
83
HIV-associated lipodystrophy.
[11737397] HIV Med 2(3): 166-73 (2001)
2008  
84
The role of HIV in serious diseases other than AIDS.
[19005264] AIDS 22(18): 2409-18 (2008)
2008  
85
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
[18981767] AIDS 22(17): 2279-89 (2008)
2008  
86
A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle.
[18784454] AIDS 22(15): 1909-17 (2008)
2008  
87
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.
[18615118] AIDS Rev 10(2): 67-84 (2008)
2003  
88
2000  
89
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.
[19096725] AIDS Rev 2(4): 211-228 (2000)
2010  
90
The macrophage in HIV-1 infection: from activation to deactivation?
[20380696] Retrovirology 7(): 33 (2010)
2010  
91
Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.
[20380694] Retrovirology 7(): 32 (2010)
2010  
92
Journey to the heart of macrophages: the delicate relationship between HIV-1 and a multifaceted cell type.
[20374630] Retrovirology 7(): 28 (2010)
2009  
93
Regulation of HIV-1 transcription in cells of the monocyte-macrophage lineage.
[20030845] Retrovirology 6(): 118 (2009)
2009  
94
On the steps of cell-to-cell HIV transmission between CD4 T cells.
[19825175] Retrovirology 6(): 89 (2009)
2009  
95
HIV interactions with monocytes and dendritic cells: viral latency and reservoirs.
[19486514] Retrovirology 6(): 51 (2009)
2009  
96
Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors.
[19265512] Retrovirology 6(): 25 (2009)
2006  
97
HIV-1 associated dementia: symptoms and causes.
[16712719] Retrovirology 3(): 28 (2006)
2010  
98
Abacavir/lamivudine combination in the treatment of HIV: a review.
[20234788] Ther Clin Risk Manag 6(): 83-94 (2010)
2009  
99
Pharmacotherapy of pediatric and adolescent HIV infection.
[19707256] Ther Clin Risk Manag 5(3): 469-84 (2009)
2008  
100
Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naive patients.
[19337434] Ther Clin Risk Manag 4(6): 1281-4 (2008)
2008  
101
Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.
[19209283] Ther Clin Risk Manag 4(5): 1023-33 (2008)
2008  
102
New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists.
[18728830] Ther Clin Risk Manag 4(2): 473-85 (2008)
2010  
103
Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection.
[20694071] Core Evid 4(): 149-58 (2010)
2010  
104
Raltegravir: The evidence of its therapeutic value in HIV-1 infection.
[20694070] Core Evid 4(): 131-47 (2010)
2000  
105
The United States in 1981: the appearance of AIDS.
[10725828] Eur J Dermatol 10(3): 242 (2000)
2009  
106
Antiretroviral drug resistance in human immunodeficiency virus type 2.
[19470514] Antimicrob Agents Chemother 53(9): 3611-9 (2009)
1992  
107
Antiretroviral therapy: reverse transcriptase inhibition.
[1376595] Antimicrob Agents Chemother 36(2): 245-54 (1992)
2009  
108
Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities.
[19578082] J Antimicrob Chemother 64(3): 437-40 (2009)
2008  
109
Current perspectives on the management and prevention of antiretroviral-associated lipoatrophy.
[18703527] J Antimicrob Chemother 62(5): 866-71 (2008)
2008  
110
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options.
[18565973] J Antimicrob Chemother 62(4): 648-60 (2008)
2006  
111
HIV entry inhibitors: mechanisms of action and resistance pathways.
[16464888] J Antimicrob Chemother 57(4): 619-27 (2006)
2005  
112
Cyclotriazadisulfonamides: promising new CD4-targeted anti-HIV drugs.
[15980096] J Antimicrob Chemother 56(2): 270-2 (2005)
2004  
113
The intracellular pharmacology of antiretroviral protease inhibitors.
[15537695] J Antimicrob Chemother 54(6): 982-90 (2004)
2004  
114
A long-term latent reservoir for HIV-1: discovery and clinical implications.
[15163657] J Antimicrob Chemother 54(1): 6-9 (2004)
2004  
115
Starting highly active antiretroviral therapy: why, when and response to HAART.
[15163656] J Antimicrob Chemother 54(1): 10-3 (2004)
2004  
116
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
[14657084] J Antimicrob Chemother 53(1): 4-9 (2004)
2003  
117
How does HAART lead to the resolution of Kaposi's sarcoma?
[12668573] J Antimicrob Chemother 51(5): 1095-8 (2003)
2003  
118
Treatment of advanced HIV infection.
[12562685] J Antimicrob Chemother 51(2): 225-7 (2003)
2003  
119
Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART.
[12562683] J Antimicrob Chemother 51(2): 213-7 (2003)
2003  
120
HIV protease inhibitors: antiretroviral agents with anti-inflammatory, anti-angiogenic and anti-tumour activity.
[12562682] J Antimicrob Chemother 51(2): 207-11 (2003)
1996  
121
Non-HIV AIDS: nature and strategies for its management.
[8818839] J Antimicrob Chemother 37 Suppl B(-): 171-83 (1996)
1996  
122
1996  
123
Management of malignancy in HIV infection.
[8818835] J Antimicrob Chemother 37 Suppl B(-): 121-33 (1996)
1996  
124
Mycobacteriosis and HIV infection: the new public health challenge.
[8818834] J Antimicrob Chemother 37 Suppl B(-): 113-20 (1996)
1996  
125
Antivirals in the context of HIV disease.
[8818833] J Antimicrob Chemother 37 Suppl B(-): 97-112 (1996)
1996  
126
1996  
127
1996  
128
Recently recognised microbial enteropathies and HIV infection.
[8818830] J Antimicrob Chemother 37 Suppl B(-): 61-70 (1996)
1996  
129
Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis.
[8818829] J Antimicrob Chemother 37 Suppl B(-): 55-60 (1996)
1996  
130
2006  
131
Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways.
[16760313] Microbiol Mol Biol Rev 70(2): 548-63 (2006)
2000  
132
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.
[11104817] Microbiol Mol Biol Rev 64(4): 725-45 (2000)
1996  
133
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions.
[8801439] Microbiol Rev 60(2): 386-406 (1996)
1995  
134
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection.
[7708013] Microbiol Rev 59(1): 63-93 (1995)
1993  
135
Pathogenesis of human immunodeficiency virus infection.
[8464405] Microbiol Rev 57(1): 183-289 (1993)
1991  
136
Genetic regulation of human immunodeficiency virus.
[1886517] Microbiol Rev 55(2): 193-205 (1991)
1998  
137
Protease inhibitors as antiviral agents.
[9767059] Clin Microbiol Rev 11(4): 614-27 (1998)
1997  
138
Role of dendritic cells in immunopathogenesis of human immunodeficiency virus infection.
[9105759] Clin Microbiol Rev 10(2): 358-67 (1997)
1996  
139
Pediatric human immunodeficiency virus infection.
[8894346] Clin Microbiol Rev 9(4): 448-68 (1996)
1996  
140
Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection.
[8964032] Clin Microbiol Rev 9(2): 135-47 (1996)
1995  
141
Cutaneous manifestations of opportunistic infections in patients infected with human immunodeficiency virus.
[7553576] Clin Microbiol Rev 8(3): 440-50 (1995)
1993  
142
Human immunodeficiency virus type 1 infection of the brain.
[8269391] Clin Microbiol Rev 6(4): 339-66 (1993)
1992  
143
Laboratory methods for early detection of human immunodeficiency virus type 1 in newborns and infants.
[1498766] Clin Microbiol Rev 5(3): 238-47 (1992)
1995  
144
Antiviral therapy for human immunodeficiency virus infections.
[7542558] Clin Microbiol Rev 8(2): 200-39 (1995)
1994  
145
Markers predicting progression of human immunodeficiency virus-related disease.
[8118788] Clin Microbiol Rev 7(1): 14-28 (1994)
1989  
146
Mycobacterial disease, immunosuppression, and acquired immunodeficiency syndrome.
[2680057] Clin Microbiol Rev 2(4): 360-77 (1989)
1989  
147
Antigen detection for human immunodeficiency virus.
[2670189] Clin Microbiol Rev 2(3): 241-9 (1989)
1988  
148
Practical diagnostic testing for human immunodeficiency virus.
[3060241] Clin Microbiol Rev 1(1): 124-38 (1988)
2004  
149
Tuberculosis in HIV-infected patients: a comprehensive review.
[15113314] Clin Microbiol Infect 10(5): 388-98 (2004)
2003  
150
Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS.
[12810858] J Gen Virol 84(Pt 7): 1649-61 (2003)
2002  
151
Human immunodeficiency virus type 2.
[12029140] J Gen Virol 83(Pt 6): 1253-65 (2002)
1998  
152
Studies of viral co-factors for human immunodeficiency virus in vitro and in vivo.
[9472605] J Gen Virol 79 ( Pt 2)(-): 213-20 (1998)
2007  
153
Cytopathic mechanisms of HIV-1.
[17945027] Virol J 4(): 100 (2007)
2001  
154
Mitochondrial toxicity and HIV therapy.
[11402222] Sex Transm Infect 77(3): 158-73 (2001)
2005  
155
HIV-associated lipodystrophy syndrome: A review of clinical aspects.
[18159551] Can J Infect Dis Med Microbiol 16(4): 233-43 (2005)
2006  
156
Defective virus drives human immunodeficiency virus infection, persistence, and pathogenesis.
[16829607] Clin Vaccine Immunol 13(7): 715-21 (2006)
2000  
157
1999  
158
Current concepts in human immunodeficiency virus infection and AIDS.
[10225826] Clin Diagn Lab Immunol 6(3): 295-305 (1999)
1999  
159
Interactions of HIV-1 with antigen-presenting cells.
[10457195] Immunol Cell Biol 77(4): 289-303 (1999)
1992  
160
Diversity and variation in human immunodeficiency virus: implications for immune control.
[1452223] Immunol Cell Biol 70 ( Pt 3)(-): 215-21 (1992)
2010  
161
The good and evil of complement activation in HIV-1 infection.
[20228834] Cell Mol Immunol 7(5): 334-40 (2010)
2007  
162
Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.
[17892849] Immunity 27(3): 406-16 (2007)
2002  
163
Live and let die: Nef functions beyond HIV replication.
[11970873] Immunity 16(4): 493-7 (2002)
2001  
164
Resistance is futile: assimilation of cellular machinery by HIV-1.
[11728331] Immunity 15(5): 687-90 (2001)
1998  
165
HIV-induced immunopathogenesis.
[9846480] Immunity 9(5): 587-93 (1998)
1998  
166
HIV nef: the mother of all evil?
[9806629] Immunity 9(4): 433-7 (1998)
1997  
167
T cell turnover in HIV-1 disease.
[9390682] Immunity 7(5): 583-9 (1997)
2008  
168
Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination.
[18388299] J Leukoc Biol 84(1): 27-49 (2008)
2008  
169
Antiviral NK cell responses in HIV infection: I. NK cell receptor genes as determinants of HIV resistance and progression to AIDS.
[18388298] J Leukoc Biol 84(1): 1-26 (2008)
2006  
170
Monocyte-derived macrophages and myeloid cell lines as targets of HIV-1 replication and persistence.
[16946020] J Leukoc Biol 80(5): 1018-30 (2006)
2006  
171
Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies.
[16931601] J Leukoc Biol 80(5): 1103-10 (2006)
2006  
172
HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes.
[16923919] J Leukoc Biol 80(5): 965-72 (2006)
2006  
173
HIV interactions with dendritic cells: has our focus been too narrow?
[16923917] J Leukoc Biol 80(5): 1001-12 (2006)
2006  
174
HIV regulation of the IL-7R: a viral mechanism for enhancing HIV-1 replication in human macrophages in vitro.
[16614257] J Leukoc Biol 79(6): 1328-38 (2006)
2003  
175
Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection.
[14595004] J Leukoc Biol 74(5): 691-701 (2003)
2003  
176
Immunodeficiency virus exploitation of dendritic cells in the early steps of infection.
[12960236] J Leukoc Biol 74(5): 683-90 (2003)
2003  
177
Regulation of HIV-1 gene transcription: from lymphocytes to microglial cells.
[12960235] J Leukoc Biol 74(5): 736-49 (2003)
2003  
178
The contribution of monocyte infection and trafficking to viral persistence, and maintenance of the viral reservoir in HIV infection.
[12960232] J Leukoc Biol 74(5): 635-41 (2003)
2003  
179
The role of dendritic cell C-type lectin receptors in HIV pathogenesis.
[12960229] J Leukoc Biol 74(5): 710-8 (2003)
2003  
180
Macrophage HIV-1 infection and the gastrointestinal tract reservoir.
[12960227] J Leukoc Biol 74(5): 642-9 (2003)
2003  
181
Viral and host cofactors facilitate HIV-1 replication in macrophages.
[12960226] J Leukoc Biol 74(5): 726-35 (2003)
1999  
182
Molecular pathway involved in HIV-1-induced CNS pathology: role of viral regulatory protein, Tat.
[10204574] J Leukoc Biol 65(4): 458-65 (1999)
1997  
183
Immunosuppressive retroviral peptides: immunopathological implications for immunosuppressive influences of retroviral infections.
[9201256] J Leukoc Biol 61(6): 654-66 (1997)
1994  
184
Biology of the mononuclear phagocyte system of the central nervous system and HIV infection.
[8083615] J Leukoc Biol 56(3): 399-406 (1994)
1994  
185
The neuropathogenesis of HIV-1 infection.
[8083614] J Leukoc Biol 56(3): 389-98 (1994)
1994  
186
Macrophages/microglia and the pathophysiology of CNS injuries in AIDS.
[8083613] J Leukoc Biol 56(3): 387-8 (1994)
1988  
187
Role of the mononuclear phagocyte system in the development of acquired immunodeficiency syndrome (AIDS).
[3275735] J Leukoc Biol 43(1): 91-7 (1988)
2008  
188
25 years of HIV research on virology, virus restriction, immunopathogenesis, genes and vaccines.
[18761662] Clin Exp Immunol 154(1): 6-14 (2008)
2008  
189
Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges.
[18373700] Clin Exp Immunol 152(2): 201-10 (2008)
1984  
190
The acquired immune deficiency syndrome.
[6370516] Clin Exp Immunol 56(1): 1-13 (1984)
2009  
191
What we still don't know about AIDS.
[20003177] J Biol 8(10): 87 (2009)
2005  
192
Molecular mechanisms of HIV-1 associated neurodegeneration.
[16052077] J Biosci 30(3): 391-405 (2005)
2003  
193
HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.
[12734410] J Biosci 28(3): 323-35 (2003)
2005  
194
AIDS and associated malignancies.
[16354573] Cell Res 15(11-12): 947-52 (2005)
2003  
195
New insights into the immunology and evolution of HIV.
[12643344] Cell Res 13(1): 1-7 (2003)
2001  
196
The burden of proof and the origin of acquired immune deficiency syndrome.
[11405944] Philos Trans R Soc Lond B Biol Sci 356(1410): 939-43 (2001)
2001  
197
The origin of acquired immune deficiency syndrome: Can science afford to ignore it?
[11405943] Philos Trans R Soc Lond B Biol Sci 356(1410): 935-8 (2001)
2001  
198
The earliest cases of human immunodeficiency virus type 1 group M in Congo-Kinshasa, Rwanda and Burundi and the origin of acquired immune deficiency syndrome.
[11405940] Philos Trans R Soc Lond B Biol Sci 356(1410): 923-5 (2001)
2001  
199
The origins of acquired immune deficiency syndrome viruses: where and when?
[11405934] Philos Trans R Soc Lond B Biol Sci 356(1410): 867-76 (2001)
2001  
200
Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution.
[11405933] Philos Trans R Soc Lond B Biol Sci 356(1410): 855-66 (2001)
2001  
201
2001  
202
Experimental oral polio vaccines and acquired immune deficiency syndrome.
[11405924] Philos Trans R Soc Lond B Biol Sci 356(1410): 803-14 (2001)
2007  
203
Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
[18341200] Indian J Biochem Biophys 44(5): 269-75 (2007)
2006  
204
Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists.
[17699198] Clin J Am Soc Nephrol 1(1): 117-29 (2006)
1993  
205
The pathogenesis of the neurological complications of HIV-1 infection.
[8244348] Genitourin Med 69(5): 333-40 (1993)
1991  
206
Clinical, virological and immunological features of primary HIV-1 infection.
[1743707] Genitourin Med 67(5): 367-73 (1991)
1999  
207
Neoplastic complications of HIV infection.
[10631453] Ann Oncol 10(11): 1271-86 (1999)
2005  
208
Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma.
[16020424] CA Cancer J Clin 55(4): 229-41; 260-1, 264 (2005)
1992  
209
Malignant neoplasms associated with human immunodeficiency virus infection.
[1540853] CA Cancer J Clin 42(2): 74-95 (1992)
2004  
210
Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients.
[15197806] Cancer 100(12): 2627-36 (2004)
1999  
211
Cancers in children infected with the human immunodeficiency virus.
[10476542] Oncologist 4(4): 309-17 (1999)
1990  
212
Immunopathogenesis of human immunodeficiency virus infection.
[1974824] Cancer Res 50(17 Suppl): 5612S-5617S (1990)
1995  
213
Identifying and treating HIV-related oral conditions: a clinical grand rounds approach.
[7594011] J Am Dent Assoc 126(10): 1394-400 (1995)
1994  
214
HIV-related tumors of the oral cavity.
[7858081] Crit Rev Oral Biol Med 5(2): 159-85 (1994)
1993  
215
HIV in the oral cavity: virus, viral inhibitory activity, and antiviral antibodies: a review.
[8373998] Crit Rev Oral Biol Med 4(3-4): 461-6 (1993)
1992  
216
HIV-related infections of the oral cavity.
[1571472] Crit Rev Oral Biol Med 3(3): 207-31 (1992)
1986  
217
The neuropathology of AIDS. UCLA experience and review.
[2876640] Am J Pathol 124(3): 537-58 (1986)
1983  
218
Autopsy pathology in the acquired immune deficiency syndrome.
[6311021] Am J Pathol 112(3): 357-82 (1983)
2006  
219
Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City.
[16983127] Ann Intern Med 145(6): 397-406 (2006)
1999  
220
1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Infectious Diseases Society of American.
[10610640] Ann Intern Med 131(11): 873-908 (1999)
2006  
221
AIDS-related lymphoproliferative disease.
[16099881] Blood 107(1): 13-20 (2006)
2003  
222
2001  
223
1991  
224
Opportunistic protozoan infections in human immunodeficiency virus disease: review highlighting diagnostic and therapeutic aspects.
[2013618] J Clin Pathol 44(3): 182-93 (1991)
1988  
225
Haematological abnormalities in human immunodeficiency virus (HIV) disease.
[3045157] J Clin Pathol 41(7): 711-5 (1988)
1991  
226
The AIDS virus. What we know and what we can do about it.
[1687714] West J Med 155(5): 481-7 (1991)
1998  
227
Pulmonary complications of HIV infection: autopsy findings.
[9596298] Chest 113(5): 1225-9 (1998)
1997  
228
1989  
229
Imaging of infants and children with AIDS.
[2650478] AJR Am J Roentgenol 152(5): 1033-41 (1989)
1988  
230
CNS complications of AIDS: CT and MR findings.
[2841835] AJR Am J Roentgenol 151(3): 449-54 (1988)
1986  
231
Neuroradiologic findings in AIDS: a review of 200 cases.
[3490168] AJR Am J Roentgenol 147(5): 977-83 (1986)
1986  
232
Abdominal CT in acquired immunodeficiency syndrome.
[3510046] AJR Am J Roentgenol 146(1): 7-13 (1986)
1986  
233
Multifocal abnormalities of the gastrointestinal tract in AIDS.
[3484397] AJR Am J Roentgenol 146(1): 1-5 (1986)
1985  
234
Cranial CT in acquired immunodeficiency syndrome: spectrum of diseases and optimal contrast enhancement technique.
[3876751] AJR Am J Roentgenol 145(5): 929-40 (1985)
1989  
235
The diagnostic role of nuclear medicine in the acquired immunodeficiency syndrome.
[2685192] J Nucl Med 30(12): 1935-45 (1989)
1994  
236
Acquired immunodeficiency syndrome and its ocular complications.
[7927632] Indian J Ophthalmol 42(2): 51-63 (1994)
1988  
237
Diagnosis and management of ocular lesions in acquired immune deficiency syndrome.
[2855324] Indian J Ophthalmol 36(4): 151-5 (1988)
1995  
238
Ocular manifestations of HIV infection.
[8719695] Trans Am Ophthalmol Soc 93(-): 623-83 (1995)
1984  
239
The retinal lesions of the acquired immune deficiency syndrome.
[6100147] Trans Am Ophthalmol Soc 82(-): 447-91 (1984)
2008  
240
From the archives of the AFIP: central nervous system infections associated with human immunodeficiency virus infection: radiologic-pathologic correlation.
[19001657] Radiographics 28(7): 2033-58 (2008)
2006  
241
Cardiovascular complications of human immunodeficiency virus infection.
[16418253] Radiographics 26(1): 213-31 (2006)
2004  
242
Imaging findings in musculoskeletal complications of AIDS.
[15256627] Radiographics 24(4): 1029-49 (2004)
2006  
243
HIV-1 infection: is it time to reconsider our concepts?
[16786149] Int J Mol Med 18(1): 3-8 (2006)
1998  
244
Functional roles of HIV accessory proteins for viral replication (review).
[9857229] Int J Mol Med 2(4): 429-33 (1998)
2005  
245
HTLV-1 Tax nucleocytoplasmic shuttling, interaction with the secretory pathway, extracellular signaling, and implications for neurologic disease.
[16228291] J Biomed Sci 12(6): 961-74 (2005)
2001  
246
Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat.
[11385301] J Biomed Sci 8(3): 290-6 (2001)
1996  
247
AIDS Dementia and HIV-1-Induced Neurotoxicity: Possible Pathogenic Associations and Mechanisms.
[11725121] J Biomed Sci 3(6): 389-414 (1996)
2005  
248
Neuropathology of HIV/AIDS with an overview of the Indian scene.
[15817957] Indian J Med Res 121(4): 468-88 (2005)
2005  
249
2005  
250
2005  
251
2005  
252
HIV-1 viral protein R (Vpr) & host cellular responses.
[15817944] Indian J Med Res 121(4): 270-86 (2005)
2005  
253
Immunopathogenesis of HIV infection.
[15817942] Indian J Med Res 121(4): 240-55 (2005)
2005  
254
HAART & the molecular biology of AIDS dementia complex.
[15817943] Indian J Med Res 121(4): 256-69 (2005)
1993  
255
Why are there so many myths about AIDS?
[8439932] CMAJ 148(5): 745-9 (1993)
1986  
256
A guide to the investigation and treatment of patients with AIDS and AIDS-related disorders.
[3008972] CMAJ 134(9): 999-1008 (1986)
1995  
257
Gastrointestinal manifestations of acquired immunodeficiency syndrome: radiologic-pathologic correlation.
[7501857] Radiographics 15(5): 1155-78 (1995)
1992  
258
Diagnostic uses of nuclear medicine in AIDS.
[1636036] Radiographics 12(4): 731-49; discussion 749-52 (1992)
1990  
259
Acute abdomen in AIDS: CT diagnosis and triage.
[2198633] Radiographics 10(4): 621-34 (1990)
1989  
260
Diseases of the chest in AIDS: CT diagnosis.
[2678294] Radiographics 9(5): 827-57 (1989)
2009  
261
Brain: non-infective and non-neoplastic manifestations of HIV.
[19890119] Br J Radiol 82(983): 956-65 (2009)
1988  
262
White matter disease in AIDS: findings at MR imaging.
[3174991] Radiology 169(2): 445-8 (1988)
1988  
263
A radiologist looks at AIDS: imaging evaluation based on symptom complexes.
[3275986] Radiology 166(2): 553-62 (1988)
1986  
264
Pulmonary manifestations of AIDS: review of 106 episodes.
[3489955] Radiology 161(1): 87-93 (1986)
1986  
265
Gastrointestinal complications of AIDS: radiologic features.
[3003792] Radiology 158(3): 597-603 (1986)
2005  
266
Cerebral MR imaging in uninfected children born to HIV-seropositive mothers and perinatally exposed to zidovudine.
[15814907] AJNR Am J Neuroradiol 26(4): 695-701 (2005)
2005  
267
Perinatal exposure to antiretroviral agents: risks and benefits.
[15814903] AJNR Am J Neuroradiol 26(4): 689-92 (2005)
2005  
268
A new challenge for the neuroradiologist: MR recognition of mitochondrial dysfunction in children born of HIV-seropositive mothers on antiretroviral therapy.
[15814902] AJNR Am J Neuroradiol 26(4): 687-9 (2005)
2003  
269
Mass lesions of the brain in AIDS: the dilemmas of distinguishing toxoplasmosis from primary CNS lymphoma.
[12695179] AJNR Am J Neuroradiol 24(4): 554-5 (2003)
1999  
270
AIDS-associated myelopathy: clinical severity, MR findings, and underlying etiologies.
[10512214] AJNR Am J Neuroradiol 20(8): 1387-8 (1999)
2010  
271
AIDS treatment with novel anti-HIV compounds improved by nanotechnology.
[20373061] AAPS J 12(3): 272-8 (2010)
2008  
272
A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections.
[18431651] AAPS PharmSciTech 9(2): 505-20 (2008)
2008  
273
The viral etiology of AIDS-associated malignancies.
[18086422] Adv Pharmacol 56(-): 509-57 (2008)
2011  
274
Management of HIV infection in treatment-naive patients: a review of the most current recommendations.
[21593227] Am J Health Syst Pharm 68(11): 991-1001 (2011)
2011  
275
HIV-related neuromuscular diseases: nemaline myopathy, amyotrophic lateral sclerosis and bibrachial amyotrophic diplegia.
[21842590] Acta Myol 30(1): 29-31 (2011)
2007  
276
Oncogenic viruses in AIDS: mechanisms of disease and intrathoracic manifestations.
[17954644] AJR Am J Roentgenol 189(5): 1082-7 (2007)
2004  
277
Dialyzing a patient with human immunodeficiency virus infection: what a nephrologist needs to know.
[15452404] Am J Nephrol 24(5): 511-21 (2004)
2010  
278
The treatment of HIV-associated nephropathy.
[20005490] Adv Chronic Kidney Dis 17(1): 59-71 (2010)
2010  
279
Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene.
[20005488] Adv Chronic Kidney Dis 17(1): 44-51 (2010)
2010  
280
Screening for chronic kidney disease in HIV-infected patients.
[20005486] Adv Chronic Kidney Dis 17(1): 26-35 (2010)
2011  
281
The neurobiology of HIV dementia: implications for practice in South Africa.
[21509406] Afr J Psychiatry (Johannesbg) 14(1): 17-22 (2011)
2002  
282
Violence during pregnancy among women with or at risk for HIV infection.
[11867312] Am J Public Health 92(3): 367-70 (2002)
2009  
283
Review: the need for smoking cessation among HIV-positive smokers.
[19537951] AIDS Educ Prev 21(3 Suppl): 14-27 (2009)
2009  
284
Effect of cigarette smoking on HIV acquisition, progression, and mortality.
[19537952] AIDS Educ Prev 21(3 Suppl): 28-39 (2009)
2009  
285
Utilization of medical treatments and adherence to antiretroviral therapy among HIV-positive adults with histories of childhood sexual abuse.
[19260772] AIDS Patient Care STDS 23(4): 259-66 (2009)
2009  
286
Hypothesis of snake and insect venoms against Human Immunodeficiency Virus: a review.
[19922674] AIDS Res Ther 6(-): 25 (2009)
2011  
287
Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.
[21490779] AIDS Res Treat 2011(-): 463704 (2011)
2010  
288
Virologic and immunologic response to HAART, by age and regimen class.
[20829678] AIDS 24(16): 2469-79 (2010)
2009  
289
Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities.
[19349851] AIDS 23(8): 875-85 (2009)
2010  
290
Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses?
[19733595] Antiviral Res 85(1): 295-302 (2010)
2010  
291
Novel approaches to inhibiting HIV-1 replication.
[19782103] Antiviral Res 85(1): 119-41 (2010)
2010  
292
Development of topical microbicides to prevent the sexual transmission of HIV.
[19874851] Antiviral Res 85(1): 142-58 (2010)
2008  
293
The structural biology of HIV assembly.
[18406133] Curr Opin Struct Biol 18(2): 203-17 (2008)
2009  
294
2010  
295
Chromatin dynamics associated with HIV-1 Tat-activated transcription.
[19716452] Biochim Biophys Acta 1799(3-4): 275-85 (2010)
2011  
296
Seek and treat: HIV update 2011.
[21285341] Cleve Clin J Med 78(2): 95-100 (2011)
2007  
297
Viral infections and the kidney: HIV, hepatitis B, and hepatitis C.
[17506240] Cleve Clin J Med 74(5): 353-60 (2007)
2005  
298
2011  
299
Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals.
[21799644] World J Gastroenterol 17(25): 2987-91 (2011)
2011  
300
Hepatitis B and C infection and liver disease trends among human immunodeficiency virus-infected individuals.
[21528052] World J Gastroenterol 17(14): 1807-16 (2011)
2009  
301
Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review.
[19673011] World J Gastroenterol 15(30): 3713-24 (2009)
2009  
302
Transgenic and infectious animal models of HIV-associated nephropathy.
[19497967] J Am Soc Nephrol 20(11): 2296-304 (2009)
2007  
303
2009  
304
Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy.
[19288142] Pediatr Nephrol 24(11): 2109-19 (2009)
2002  
305
Cardiovascular manifestations of HIV infection.
[12221062] Circulation 106(11): 1420-5 (2002)
2005  
306
What a cardiologist needs to know about patients with human immunodeficiency virus infection.
[16365213] Circulation 112(25): 3947-57 (2005)
2006  
307
Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.
[16323102] Clin Infect Dis 42(1): 126-31 (2006)
2006  
308
HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.
[16619164] Clin Infect Dis 42(10): 1488-95 (2006)
2002  
309
Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature.
[11850865] Clin Infect Dis 34(6): 838-46 (2002)
2002  
310
Focal neurological disease in patients with acquired immunodeficiency syndrome.
[11731953] Clin Infect Dis 34(1): 103-15 (2002)
2002  
311
Clinical indicators of immune restoration following highly active antiretroviral therapy.
[11740712] Clin Infect Dis 34(2): 224-33 (2002)
2002  
312
Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.
[11740715] Clin Infect Dis 34(2): 248-59 (2002)
2010  
313
HIV-associated tuberculosis: clinical update.
[20388036] Clin Infect Dis 50(10): 1377-86 (2010)
2010  
314
The changing natural history of tuberculosis and HIV coinfection in an urban area of hyperendemicity.
[20397950] Clin Infect Dis 50 Suppl 3(-): S208-14 (2010)
2010  
315
Prevention of tuberculosis in people living with HIV.
[20397951] Clin Infect Dis 50 Suppl 3(-): S215-22 (2010)
2010  
316
HIV infection-related tuberculosis: clinical manifestations and treatment.
[20397952] Clin Infect Dis 50 Suppl 3(-): S223-30 (2010)
2007  
317
Tipranavir: a new option for the treatment of drug-resistant HIV infection.
[17712762] Clin Infect Dis 45(6): 761-9 (2007)
2007  
318
Epidemiologic investigation of a cluster of workplace HIV infections in the adult film industry: Los Angeles, California, 2004.
[17173235] Clin Infect Dis 44(2): 301-5 (2007)
2007  
319
Dysregulated energy expenditure in HIV-infected patients: a mechanistic review.
[17479951] Clin Infect Dis 44(11): 1509-17 (2007)
2009  
320
Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks.
[19133800] Clin Infect Dis 48(4): 473-5 (2009)
2009  
321
Has human immunodeficiency virus become more virulent?
[19309305] Clin Infect Dis 48(9): 1293-5 (2009)
2009  
322
Are all subtypes created equal? The effectiveness of antiretroviral therapy against non-subtype B HIV-1.
[19331584] Clin Infect Dis 48(9): 1306-9 (2009)
2008  
323
Leprosy reversal reaction as immune reconstitution inflammatory syndrome in patients with AIDS.
[18269334] Clin Infect Dis 46(6): e56-60 (2008)
2008  
324
Do Vgamma2Vdelta2 T cells influence HIV disease progression?
[18419458] Clin Infect Dis 46(9): 1473-5 (2008)
2009  
325
HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
[19072245] Clin Infect Dis 48(2): 214-21 (2009)
2009  
326
HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal.
[19025493] Clin Infect Dis 48(1): 101-7 (2009)
2006  
327
Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review.
[16779751] Clin Infect Dis 43(2): 223-33 (2006)
2005  
328
HIV-1 infection and AIDS: consequences for the central nervous system.
[15832177] Cell Death Differ 12 Suppl 1(-): 878-92 (2005)
2005  
329
2009  
330
Biochemical basis of immunological and retroviral responses to DNA-targeted cytosine deamination by activation-induced cytidine deaminase and APOBEC3G.
[19684020] J Biol Chem 284(41): 27761-5 (2009)
2011  
331
Treatment Considerations in Painful HIV-Related Neuropathy.
[22086103] Pain Physician 14(6): E505-24 (2011)
2008  
332
Approach to the human immunodeficiency virus-infected patient with lipodystrophy.
[18685115] J Clin Endocrinol Metab 93(8): 2937-45 (2008)
2004  
333
Metabolic bone disease in human immunodeficiency virus-infected children.
[14715821] J Clin Endocrinol Metab 89(1): 21-3 (2004)
2009  
334
Whither recombinant human leptin treatment for HIV-associated lipoatrophy and the metabolic syndrome?
[19349474] J Clin Endocrinol Metab 94(4): 1089-91 (2009)
2009  
335
HIV-associated lymphomas and gamma-herpesviruses.
[18955561] Blood 113(6): 1213-24 (2009)
2011  
336
2011  
337
The role of glycosphingolipids in HIV/AIDS.
[21524384] Discov Med 11(59): 303-13 (2011)
2008  
338
Role of HIV Gp41 mediated fusion/hemifusion in bystander apoptosis.
[18500445] Cell Mol Life Sci 65(20): 3134-44 (2008)
2008  
339
The spread, treatment, and prevention of HIV-1: evolution of a global pandemic.
[18382737] J Clin Invest 118(4): 1244-54 (2008)
2010  
340
Intravaginal practices, vaginal infections and HIV acquisition: systematic review and meta-analysis.
[20161749] PLoS One 5(2): e9119 (2010)
2010  
341
2009  
342
Reversal of HIV-1 latency with anti-microRNA inhibitors.
[18761423] Int J Biochem Cell Biol 41(3): 451-4 (2009)
2007  
343
Autophagy and CD4+ T lymphocyte destruction by HIV-1.
[17012832] Autophagy 3(1): 32-4 (2007)
2008  
344
What is the role of autophagy in HIV-1 infection?
[17993779] Autophagy 4(3): 273-5 (2008)
2002  
345
Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.
[12001033] J Infect Dis 185 Suppl 2(-): S123-7 (2002)
2011  
346
HIV-1 integrase inhibitor resistance and its clinical implications.
[21459813] J Infect Dis 203(9): 1204-14 (2011)
2010  
347
Clinical management of acute HIV infection: best practice remains unknown.
[20846034] J Infect Dis 202 Suppl 2(-): S278-88 (2010)
2010  
348
HIV-1 transmission biology: selection and characteristics of infecting viruses.
[20846035] J Infect Dis 202 Suppl 2(-): S289-96 (2010)
2010  
349
Innate immune activation in primary HIV-1 infection.
[20846036] J Infect Dis 202 Suppl 2(-): S297-301 (2010)
2010  
350
T cell immunity in acute HIV-1 infection.
[20846037] J Infect Dis 202 Suppl 2(-): S302-8 (2010)
2010  
351
Viral evolution and escape during acute HIV-1 infection.
[20846038] J Infect Dis 202 Suppl 2(-): S309-14 (2010)
2010  
352
The humoral response to HIV-1: new insights, renewed focus.
[20846039] J Infect Dis 202 Suppl 2(-): S315-22 (2010)
2010  
353
Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection.
[20846040] J Infect Dis 202 Suppl 2(-): S323-6 (2010)
2010  
354
Rescue of severely immunocompromised HIV-positive persons.
[20942649] J Infect Dis 202(10): 1467-9 (2010)
2010  
355
The detection of acute HIV infection.
[20846033] J Infect Dis 202 Suppl 2(-): S270-7 (2010)
2010  
356
HIV neutralizing antibodies: clinical correlates and implications for vaccines.
[20170372] J Infect Dis 201(7): 981-3 (2010)
2010  
357
A novel use for an old drug: the potential for minocycline as anti-HIV adjuvant therapy.
[20205572] J Infect Dis 201(8): 1115-7 (2010)
2010  
358
Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?
[20151843] J Infect Dis 201(6): 797-9 (2010)
2007  
359
Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.
[17624828] J Infect Dis 196 Suppl 1(-): S63-75 (2007)
2011  
360
Converging strategies in expression of human complex retroviruses.
[21994786] Viruses 3(8): 1395-414 (2011)
2011  
361
The natural killer cell cytotoxic function is modulated by HIV-1 accessory proteins.
[21994772] Viruses 3(7): 1091-111 (2011)
2011  
362
Innate antiviral response: role in HIV-1 infection.
[21994776] Viruses 3(7): 1179-203 (2011)
2011  
363
CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis.
[21994747] Viruses 3(5): 586-612 (2011)
2011  
364
How HIV takes advantage of the cytoskeleton in entry and replication.
[21994733] Viruses 3(4): 293-311 (2011)
2011  
365
Clinical management of HIV drug resistance.
[21994737] Viruses 3(4): 347-78 (2011)
2011  
366
Rev variation during persistent lentivirus infection.
[21994723] Viruses 3(1): 1-11 (2011)
2011  
367
How HIV-1 takes advantage of the cytoskeleton during replication and cell-to-cell transmission.
[21994805] Viruses 3(9): 1757-76 (2011)
2010  
368
HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate.
[21994659] Viruses 2(4): 880-99 (2010)
2010  
369
HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors.
[21994660] Viruses 2(4): 900-26 (2010)
2010  
370
HIV-1 Entry, Inhibitors, and Resistance.
[21994672] Viruses 2(5): 1069-105 (2010)
2010  
371
HIV-1 Virological Synapse is not Simply a Copycat of the Immunological Synapse.
[20890395] Viruses 2(5): 1239-60 (2010)
2010  
372
HIV Genetic Diversity and Drug Resistance.
[21994646] Viruses 2(2): 503-31 (2010)
2007  
373
Epidemiology of human immunodeficiency virus in the United States.
[17630336] Clin Microbiol Rev 20(3): 478-88, table of contents (2007)
2009  
374
Advances and failures in preventing perinatal human immunodeficiency virus infection.
[19597011] Clin Microbiol Rev 22(3): 493-507 (2009)
2005  
375
AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy.
[15967835] Oncologist 10(6): 412-26 (2005)
2010  
376
Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.
[21160280] RNA Biol 7(6): 754-74 (2010)
2008  
377
Rheumatic conditions in human immunodeficiency virus infection.
[18413346] Rheumatology (Oxford) 47(7): 952-9 (2008)
2002  
378
HIV associated thrombotic microangiopathy.
[12357011] Postgrad Med J 78(923): 520-5 (2002)
2004  
379
Acquired immunodeficiency syndrome: manifestations in the oral cavity.
[15580133] Med Oral Patol Oral Cir Bucal 9 Suppl(-): 153-7; 148-53 (2004)
2008  
380
Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence.
[18223535] Med Oral Patol Oral Cir Bucal 13(2): E85-93 (2008)
2005  
381
Clinical practice. Management of newly diagnosed HIV infection.
[16236741] N Engl J Med 353(16): 1702-10 (2005)
2004  
382
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
[15115831] N Engl J Med 350(18): 1850-61 (2004)
2009  
383
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
[19952143] N Engl J Med 361(23): 2230-40 (2009)
2008  
384
The challenge of HIV-1 subtype diversity.
[18403767] N Engl J Med 358(15): 1590-602 (2008)
2009  
385
Clinical practice. Postexposure prophylaxis for HIV infection.
[19864675] N Engl J Med 361(18): 1768-75 (2009)
2010  
386
2003  
387
Mechanisms of lipid elevations associated with the treatment of patients with HIV infection.
[14603100] MedGenMed 5(2): 1 (2003)
2008  
388
2008  
389
HIV: mother-to-child transmission.
[19450331] Clin Evid (Online) 2008(-): - (2008)
2008  
390
A 39-year-old man with HIV-associated lipodystrophy.
[18677013] JAMA 300(9): 1056-66 (2008)
2008  
391
Factors influencing the natural history of HIV-1 infection.
[19187605] Chin Med J (Engl) 121(24): 2613-21 (2008)
2005  
392
Low-cost monitoring of HIV infected individuals on highly active antiretroviral therapy (HAART) in developing countries.
[15817948] Indian J Med Res 121(4): 345-55 (2005)
2005  
393
Human immunodeficiency virus (HIV) & sexually transmitted diseases (STDs).
[15817950] Indian J Med Res 121(4): 369-76 (2005)
2005  
394
Clinical profile of HIV in India.
[15817951] Indian J Med Res 121(4): 377-94 (2005)
2005  
395
Progress in diagnosis of opportunistic infections in HIV/AIDS.
[15817952] Indian J Med Res 121(4): 395-406 (2005)
2005  
396
Diagnosis & management of leishmania/HIV co-infection.
[15817953] Indian J Med Res 121(4): 407-14 (2005)
2005  
397
Preventive therapy for tuberculosis in HIV infected individuals.
[15817954] Indian J Med Res 121(4): 415-23 (2005)
2005  
398
Hepatitis B & hepatitis C in HIV-infection.
[15817955] Indian J Med Res 121(4): 424-50 (2005)
2005  
399
Prevention of mother-to-child transmission of HIV--an overview.
[15817958] Indian J Med Res 121(4): 489-501 (2005)
2005  
400
HIV testing technologies after two decades of evolution.
[15817961] Indian J Med Res 121(4): 519-38 (2005)
2005  
401
CD4+ T cell count as a tool to monitor HIV progression & anti-retroviral therapy.
[15817962] Indian J Med Res 121(4): 539-49 (2005)
2005  
402
HIV-TB co-infection: epidemiology, diagnosis & management.
[15817963] Indian J Med Res 121(4): 550-67 (2005)
2009  
403
Cellular & molecular basis of HIV-associated neuropathogenesis.
[19692743] Indian J Med Res 129(6): 637-51 (2009)
2010  
404
Mucocutaneous manifestations in children with human immunodeficiency virus infection.
[20826983] Indian J Dermatol Venereol Leprol 76(5): 458-66 (2010)
2006  
405
2010  
406
Immune reconstitution inflammatory syndrome after initiation of highly active anti-retroviral therapy in HIV/AIDS.
[20445313] Indian J Dermatol Venereol Leprol 76(3): 301-4 (2010)
2004  
407
2007  
408
Re-mapping the molecular features of the human immunodeficiency virus type 1 and human T-cell lymphotropic virus type 1 Brazilian sequences using a bioinformatics unit established in Salvador, Bahia, Brazil, to give support to the viral epidemiology studies.
[17426875] Mem Inst Oswaldo Cruz 102(2): 133-9 (2007)
2011  
409
Impact of current antiretroviral therapies on neuroAIDS.
[21504390] Expert Rev Anti Infect Ther 9(4): 371-4 (2011)
2010  
410
First real success for anti-HIV gel: a new start for HIV microbicides?
[21133683] Future Microbiol 5(11): 1621-3 (2010)
2010  
411
Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
[20418273] J Antimicrob Chemother 65(6): 1094-9 (2010)
2009  
412
Eradication of HIV: current challenges and new directions.
[18984648] J Antimicrob Chemother 63(1): 7-10 (2009)
2009  
413
Using HIV resistance tests in clinical practice.
[19535382] J Antimicrob Chemother 64(2): 218-22 (2009)
2008  
414
HIV and mitochondrial toxicity in children.
[17999978] J Antimicrob Chemother 61(1): 8-12 (2008)
2005  
415
Current perspectives on HIV-associated lipodystrophy syndrome.
[15905302] J Antimicrob Chemother 56(1): 6-9 (2005)
2011  
416
The discovery and development of HIV therapy: the new challenges.
[21430337] Ann Ist Super Sanita 47(1): 41-3 (2011)
2011  
417
A brief history of antiretroviral therapy of HIV infection: success and challenges.
[21430338] Ann Ist Super Sanita 47(1): 44-8 (2011)
2010  
418
HIV virology and pathogenetic mechanisms of infection: a brief overview.
[20348614] Ann Ist Super Sanita 46(1): 5-14 (2010)
2010  
419
Laboratory diagnostics for HIV infection.
[20348616] Ann Ist Super Sanita 46(1): 24-33 (2010)
2010  
420
Suggested strategies for the laboratory diagnosis of HIV infection in Italy.
[20348617] Ann Ist Super Sanita 46(1): 34-41 (2010)
2006  
421
Advances in antiretroviral therapy.
[16641526] Top HIV Med 14(1): 36-62 (2006)
2006  
422
Complications of HIV disease and antiretroviral therapy.
[16641525] Top HIV Med 14(1): 27-35 (2006)
2006  
423
Neurologic complications of HIV disease and their treatments.
[16641524] Top HIV Med 14(1): 21-6 (2006)
2010  
424
2010  
425
HIV epidemiology, testing strategies, and prevention interventions.
[20516523] Top HIV Med 18(2): 38-44 (2010)
2010  
426
Neurologic complications of HIV disease and their treatment.
[20516524] Top HIV Med 18(2): 45-55 (2010)
2010  
427
Complications of HIV disease and antiretroviral treatment.
[20516525] Top HIV Med 18(2): 57-65 (2010)
2010  
428
Advances in antiretroviral therapy.
[20516526] Top HIV Med 18(2): 66-92 (2010)
2005  
429
Antiretroviral drug resistance and resistance testing.
[16377851] Top HIV Med 13(5): 138-42 (2005)
2005  
430
Oral manifestations of HIV disease.
[16377852] Top HIV Med 13(5): 143-8 (2005)
2005  
431
Dermatologic manifestations of HIV infection.
[16377853] Top HIV Med 13(5): 149-54 (2005)
2009  
432
HIV-associated resources on the internet.
[20068262] Top HIV Med 17(5): 151-62 (2009)
2003  
433
Drug resistance mutations in HIV-1.
[14724329] Top HIV Med 11(6): 215-21 (2003)
2003  
434
Advances in antiretroviral therapy.
[12837969] Top HIV Med 11(3): 97-127 (2003)
2008  
435
Update of the Drug Resistance Mutations in HIV-1.
[19106428] Top HIV Med 16(5): 138-45 (2008)
2008  
436
Drug-drug interactions with newer antiretroviral agents.
[19106429] Top HIV Med 16(5): 146-50 (2008)
2010  
437
Dermatologic manifestations of HIV in Africa.
[20305311] Top HIV Med 18(1): 16-22 (2010)
2010  
438
Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation.
[20305309] Top HIV Med 18(1): 2-6 (2010)
2007  
439
HIV disease progression: immune activation, microbes, and a leaky gut.
[17720995] Top HIV Med 15(4): 114-7 (2007)
2007  
440
Update of the drug resistance mutations in HIV-1: 2007.
[17720996] Top HIV Med 15(4): 119-25 (2007)
2007  
441
Neurologic complications of HIV disease and their treatment.
[17485785] Top HIV Med 15(2): 32-9 (2007)
2007  
442
Complications of HIV disease and therapy.
[17485786] Top HIV Med 15(2): 40-7 (2007)
2007  
443
Advances in antiretroviral therapy.
[17485787] Top HIV Med 15(2): 48-82 (2007)
2005  
444
Complications of HIV disease and antiretroviral therapy.
[15849369] Top HIV Med 13(1): 16-23 (2005)
2005  
445
Advances in antiretroviral therapy.
[15849370] Top HIV Med 13(1): 24-44 (2005)
2009  
446
Neurologic complications of HIV disease and their treatment.
[19401607] Top HIV Med 17(2): 46-56 (2009)
2009  
447
Complications of HIV disease and antiretroviral therapy.
[19401608] Top HIV Med 17(2): 57-67 (2009)
2009  
448
Advances in antiretroviral therapy.
[19401609] Top HIV Med 17(2): 68-88 (2009)
2008  
449
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy.
[18441381] Top HIV Med 16(1): 31-60 (2008)
2008  
450
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Complications of HIV disease and therapy.
[18441380] Top HIV Med 16(1): 23-30 (2008)
2008  
451
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Neurologic complications of HIV disease and their treatment.
[18441379] Top HIV Med 16(1): 15-22 (2008)
2008  
452
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. HIV testing and prevention strategies.
[18441378] Top HIV Med 16(1): 9-14 (2008)
2008  
453
Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
[18838747] Top HIV Med 16(4): 127-33 (2008)
2008  
454
Non--AIDS-defining malignancies in HIV.
[18838745] Top HIV Med 16(4): 117-21 (2008)
2008  
455
Emerging resistance profiles of newly approved antiretroviral drugs.
[18838744] Top HIV Med 16(4): 110-6 (2008)
2005  
456
Selected rare, noninfectious syndromes associated with HIV infection.
[16082058] Top HIV Med 13(2): 75-8 (2005)
2005  
457
Metabolic complications of antiretroviral therapy.
[16082057] Top HIV Med 13(2): 70-4 (2005)
2005  
458
HIV in adolescents and young adults: half of all new infections in the United States.
[16170227] Top HIV Med 13(3): 101-5 (2005)
2009  
459
Update on cardiovascular complications in HIV infection.
[19675367] Top HIV Med 17(3): 98-103 (2009)
2006  
460
Human immunodeficiency virus infection and macrophage cholesterol metabolism.
[17056763] J Leukoc Biol 80(5): 1044-51 (2006)
2006  
461
Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases.
[16959898] J Leukoc Biol 80(5): 1052-66 (2006)
2006  
462
HIV accomplices and adversaries in macrophage infection.
[16908514] J Leukoc Biol 80(5): 973-83 (2006)
2010  
463
The macrophage: the intersection between HIV infection and atherosclerosis.
[19952353] J Leukoc Biol 87(4): 589-98 (2010)
2010  
464
Macrophage polarization and HIV-1 infection.
[20042468] J Leukoc Biol 87(4): 599-608 (2010)
2010  
465
The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.
[20042471] J Leukoc Biol 87(4): 627-32 (2010)
2010  
466
HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications.
[20130221] J Leukoc Biol 87(4): 621-6 (2010)
2010  
467
Plasmacytoid dendritic cells in HIV infection: striking a delicate balance.
[20145197] J Leukoc Biol 87(4): 609-20 (2010)
2010  
468
Macrophages: do they impact AIDS progression more than CD4 T cells?
[20053708] J Leukoc Biol 87(4): 569-73 (2010)
2010  
469
HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes.
[19801499] J Leukoc Biol 87(4): 575-88 (2010)
2002  
470
Prospects for immune reconstitution in HIV-1 infection.
[11966755] Clin Exp Immunol 127(3): 402-11 (2002)
2007  
471
2008  
472
The lymph node in HIV pathogenesis.
[18620868] Semin Immunol 20(3): 187-95 (2008)
2008  
473
The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche.
[18595731] Semin Immunol 20(3): 181-6 (2008)
2008  
474
Roles of MCP-1 in development of HIV-dementia.
[18508485] Front Biosci 13(-): 3913-8 (2008)
2011  
475
Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.
[21424110] Mol Med 17(5-6): 466-72 (2011)
2008  
476
2009  
477
Oral complications of HIV disease.
[19488613] Clinics (Sao Paulo) 64(5): 459-70 (2009)
2009  
478
Mechanistic and pharmacological analyses of HIV-1 integration.
[19389610] Methods 47(4): 225-8 (2009)
2006  
479
Dendritic-cell interactions with HIV: infection and viral dissemination.
[17063186] Nat Rev Immunol 6(11): 859-68 (2006)
2009  
480
B cells in HIV infection and disease.
[19319142] Nat Rev Immunol 9(4): 235-45 (2009)
2008  
481
Setting the stage: host invasion by HIV.
[18469831] Nat Rev Immunol 8(6): 447-57 (2008)
2012  
482
Inhibition of ER stress-mediated apoptosis in macrophages by nuclear-cytoplasmic relocalization of eEF1A by the HIV-1 Nef protein.
[22476100] Cell Death Dis 3(): e292 (2012)
2011  
483
A surprising prevention success: why did the HIV epidemic decline in Zimbabwe?
[21346807] PLoS Med 8(2): e1000414 (2011)
2007  
484
Inflammatory, oxidative and lipid perspectives on dementia in HIV-infected patients.
[20477396] Biomark Med 1(2): 221-4 (2007)
2004  
485
Initiating antiretroviral therapy in asymptomatic HIV patients.
[14977292] J Natl Med Assoc 96(2 Suppl): 13S-16S (2004)
2004  
486
Managing the metabolic and morphologic complications of HIV.
[14977293] J Natl Med Assoc 96(2 Suppl): 17S-20S (2004)
2010  
487
AIDS: a radiation oncologist's perspective.
[21358076] J Cancer Res Ther 6(4): 432-41 (2010)
2010  
488
Dyslipidemia in HIV-infected individuals.
[21340298] Braz J Infect Dis 14(6): 575-88 (2010)
2005  
489
GBV-C/HGV and HIV-1 coinfection.
[16127587] Braz J Infect Dis 9(2): 122-5 (2005)
2010  
490
2002  
491
Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease.
[12190858] J Invest Dermatol 119(2): 365-9 (2002)
2005  
492
Human immunodeficiency virus/acquired immunodeficiency syndrome and cancer: past, present, and future.
[15769998] J Natl Cancer Inst 97(6): 407-9 (2005)
2010  
493
Role of tipranavir in treatment of patients with multidrug-resistant HIV.
[20957134] Ther Clin Risk Manag 6(-): 431-41 (2010)
2007  
494
Review of tipranavir in the treatment of drug-resistant HIV.
[18472987] Ther Clin Risk Manag 3(4): 641-51 (2007)
2008  
495
Penicilliosis: an AIDS-defining disease in Asia.
[18382013] Hong Kong Med J 14(2): 88-9 (2008)
2010  
496
Imaging features of CNS involvement in AIDS.
[20119906] Diagn Interv Radiol 16(3): 193-200 (2010)
2002  
497
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.
[12617573] Ann Intern Med 137(5 Pt 2): 381-433 (2002)
2008  
498
Molluscum contagiosum in human immunodeficiency virus infected patients.
[18445935] Indian J Dent Res 19(2): 155-9 (2008)
2006  
499
The natural history of HIV infection in Africa.
[16841134] S Afr Med J 96(6): 522-3 (2006)
2009  
500
The pharmacologic management of insomnia in patients with HIV.
[19960648] J Clin Sleep Med 5(3): 251-62 (2009)
2010  
501
Identifying and characterizing recently transmitted viruses.
[20543609] Curr Opin HIV AIDS 5(4): 327-34 (2010)
2010  
502
Contribution of sexually transmitted infections to the sexual transmission of HIV.
[20543605] Curr Opin HIV AIDS 5(4): 305-10 (2010)
2010  
503
Role of acute and early HIV infection in the sexual transmission of HIV.
[20543601] Curr Opin HIV AIDS 5(4): 277-82 (2010)
2010  
504
Modelling sexual transmission of HIV: testing the assumptions, validating the predictions.
[20543600] Curr Opin HIV AIDS 5(4): 269-76 (2010)
2010  
505
Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis.
[20966640] Curr Opin HIV AIDS 5(6): 504-10 (2010)
2010  
506
Biomarkers of immune dysfunction in HIV.
[20978393] Curr Opin HIV AIDS 5(6): 498-503 (2010)
2010  
507
Th17 cell dynamics in HIV infection.
[20543590] Curr Opin HIV AIDS 5(2): 135-40 (2010)
2010  
508
Th17 cells in pathogenic simian immunodeficiency virus infection of macaques.
[20543591] Curr Opin HIV AIDS 5(2): 141-5 (2010)
2010  
509
2010  
510
Th17 and regulatory T cells: implications for AIDS pathogenesis.
[20543593] Curr Opin HIV AIDS 5(2): 151-7 (2010)
2008  
511
New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors.
[19373036] Curr Opin HIV AIDS 3(6): 642-6 (2008)
2008  
512
HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.
[19373039] Curr Opin HIV AIDS 3(6): 660-5 (2008)
2009  
513
HIV-1 entry inhibitors: an overview.
[19339945] Curr Opin HIV AIDS 4(2): 82-7 (2009)
2009  
514
CCR5 monoclonal antibodies for HIV-1 therapy.
[19339948] Curr Opin HIV AIDS 4(2): 104-11 (2009)
2009  
515
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.
[19339950] Curr Opin HIV AIDS 4(2): 118-24 (2009)
2008  
516
Mucosal immunity to HIV: a review of recent literature.
[19373019] Curr Opin HIV AIDS 3(5): 541-7 (2008)
2008  
517
Biology of HIV mucosal transmission.
[18802490] Curr Opin HIV AIDS 3(5): 534-40 (2008)
2008  
518
The mucosal barrier and immune activation in HIV pathogenesis.
[19372990] Curr Opin HIV AIDS 3(3): 356-61 (2008)
2007  
519
Unraveling the paradoxes of HIV-associated psoriasis: a review of T-cell subsets and cytokine profiles.
[17498423] Dermatol Online J 13(2): 4 (2007)
2007  
520
The design of drugs for HIV and HCV.
[18049474] Nat Rev Drug Discov 6(12): 1001-18 (2007)
2009  
521
Cardiovascular complications in the acquired immunodeficiency syndrome.
[19918668] Rev Assoc Med Bras 55(5): 621-30 (2009)
2009  
522
Etiological agents of diarrhea in patients infected by the human immunodeficiency virus-1: a review.
[19390732] Rev Inst Med Trop Sao Paulo 51(2): 59-65 (2009)
2009  
523
HIV-1 IN inhibitors: 2010 update and perspectives.
[19747122] Curr Top Med Chem 9(11): 1016-37 (2009)
2002  
524
Current approaches to diagnosis and management of ocular lesions in human immunodeficiency virus positive patients.
[12194584] Indian J Ophthalmol 50(2): 83-96 (2002)
2008  
525
Posterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome.
[18711265] Indian J Ophthalmol 56(5): 377-83 (2008)
2008  
526
Anterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome.
[18711264] Indian J Ophthalmol 56(5): 363-75 (2008)
2011  
527
Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review.
[21666786] PLoS Negl Trop Dis 5(6): e1153 (2011)
2007  
528
Maraviroc: the evidence for its potential in the management of HIV.
[21221194] Core Evid 2(1): 1-14 (2007)
2009  
529
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.
[19361855] Lancet 373(9672): 1352-63 (2009)
2006  
530
2010  
531
HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention.
[20406794] Int J Epidemiol 39(4): 1048-63 (2010)
2008  
532
Systematic review of orogenital HIV-1 transmission probabilities.
[18664564] Int J Epidemiol 37(6): 1255-65 (2008)
2011  
533
Human immunodeficiency virus-associated gastrointestinal disease: common endoscopic biopsy diagnoses.
[21559197] Patholog Res Int 2011(-): 247923 (2011)
2011  
534
Review of HIV-Related Cytopathology.
[21559199] Patholog Res Int 2011(-): 256083 (2011)
2011  
535
Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective.
[21660263] Patholog Res Int 2011(-): 359242 (2011)
2011  
536
A Review of Carcinomas Arising in the Head and Neck Region in HIV-Positive Patients.
[21660273] Patholog Res Int 2011(-): 469150 (2011)
2011  
537
Dyslipidemia and lipid management in HIV-infected patients.
[21297466] Curr Opin Endocrinol Diabetes Obes 18(2): 144-7 (2011)
2010  
538
Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection.
[20096804] Drug Discov Today 15(5-6): 186-97 (2010)
2008  
539
Recent progress in antiretrovirals--lessons from resistance.
[18468560] Drug Discov Today 13(9-10): 424-32 (2008)
2010  
540
HIV-1 vaccine development after STEP.
[20059334] Annu Rev Med 61(-): 153-67 (2010)
2009  
541
Emerging concepts in the immunopathogenesis of AIDS.
[18947296] Annu Rev Med 60(-): 471-84 (2009)
2009  
542
Management of paediatric HIV-1 resistance.
[19405216] Curr Opin Infect Dis 22(3): 256-63 (2009)
2011  
543
Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
[21181310] Curr Atheroscler Rep 13(1): 51-6 (2011)
2011  
544
HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.
[21629510] Open Med Chem J 5(-): 40-50 (2011)
2010  
545
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials.
[20974576] HIV Clin Trials 11(4): 205-19 (2010)
2002  
546
HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities.
[11894812] HIV Clin Trials 3(1): 89-98 (2002)
2004  
547
2004  
548
Enfuvirtide: antiretroviral class 4, drug 1.
[15002081] HIV Clin Trials 5(1): 1-6 (2004)
2004  
549
Treatment guidelines for HIV-associated wasting.
[15002087] HIV Clin Trials 5(1): 50-61 (2004)
2008  
550
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.
[18215981] HIV Clin Trials 9(1): 43-51 (2008)
2008  
551
Determination of the underlying cause of death in three multicenter international HIV clinical trials.
[18547904] HIV Clin Trials 9(3): 177-85 (2008)
2011  
552
HIV and HAART-Associated Dyslipidemia.
[21643501] Open Cardiovasc Med J 5(-): 49-63 (2011)
2008  
553
Human papillomavirus-related diseases in HIV-infected individuals.
[19106657] Curr Opin Oncol 20(5): 541-6 (2008)
2009  
554
Host genetic determinants of human immunodeficiency virus infection and disease progression in children.
[19190524] Pediatr Res 65(5 Pt 2): 55R-63R (2009)
2010  
555
Biomarkers predicting progression of human immunodeficiency virus-related disease.
[21811520] J Clin Med Res 2(2): 55-61 (2010)
2008  
556
Nonhuman primate models of NeuroAIDS.
[18780230] J Neurovirol 14(4): 292-300 (2008)
2008  
557
Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies.
[18780233] J Neurovirol 14(4): 318-26 (2008)
2009  
558
Acquired immunodeficiency syndrome and the blood-brain barrier.
[19306229] J Neurovirol 15(2): 111-22 (2009)
2011  
559
When patients cannot take pills: antiretroviral drug formulations for managing adult HIV infection.
[21946391] Top Antivir Med 19(3): 126-31 (2011)
2011  
560
HIV diagnostic testing: evolving technology and testing strategies.
[21852712] Top Antivir Med 19(1): 18-22 (2011)
2011  
561
Central nervous system complications of HIV infection.
[21868822] Top Antivir Med 19(2): 48-57 (2011)
2011  
562
Complications of HIV disease and antiretroviral therapy.
[21868823] Top Antivir Med 19(2): 58-68 (2011)
2011  
563
Advances in antiretroviral therapy.
[21868824] Top Antivir Med 19(2): 69-97 (2011)
2009  
564
Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine.
[19241253] Int Rev Immunol 28(1): 49-68 (2009)
2011  
565
New insights into HIV-1-primary skin disorders.
[21261982] J Int AIDS Soc 14(-): 5 (2011)
2010  
566
Highly active antiretroviral treatment for the prevention of HIV transmission.
[20205768] J Int AIDS Soc 13(-): 1 (2010)
2009  
567
HIV-associated opportunistic pneumonias.
[19645867] Respirology 14(4): 474-85 (2009)
2008  
568
Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series.
[18824430] Clin Genitourin Cancer 6(2): 86-90 (2008)
2010  
569
When to start antiretroviral therapy.
[20425559] Curr HIV AIDS Rep 7(2): 60-8 (2010)
2010  
570
Role of humoral immunity in host defense against HIV.
[20425053] Curr HIV AIDS Rep 7(1): 11-8 (2010)
2010  
571
The impact of HAART on HPV-related cervical disease.
[20946095] Curr HIV Res 8(7): 493-7 (2010)
2008  
572
Cellular reservoirs of HIV-1 and their role in viral persistence.
[18855649] Curr HIV Res 6(5): 388-400 (2008)
2010  
573
An update on Cryptococcus among HIV-infected patients.
[21139145] Int J STD AIDS 21(10): 679-84 (2010)
2009  
574
Neuromuscular diseases associated with HIV-1 infection.
[19771594] Muscle Nerve 40(6): 1043-53 (2009)
2007  
575
Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.
[18034881] Cost Eff Resour Alloc 5(-): 15 (2007)
2010  
576
Novel mechanisms of central nervous system damage in HIV infection.
[22096383] HIV AIDS (Auckl) 2(-): 39-49 (2010)
2010  
577
Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children.
[22096385] HIV AIDS (Auckl) 2(-): 59-67 (2010)
2005  
578
Neuropsychiatric manifestations of HIV infection and AIDS.
[16049567] J Psychiatry Neurosci 30(4): 237-46 (2005)
2009  
579
Cognitive neuropsychology of HIV-associated neurocognitive disorders.
[19462243] Neuropsychol Rev 19(2): 152-68 (2009)
2009  
580
Functional consequences of HIV-associated neuropsychological impairment.
[19472057] Neuropsychol Rev 19(2): 186-203 (2009)
2009  
581
HIV infection and the central nervous system: a primer.
[19415500] Neuropsychol Rev 19(2): 144-51 (2009)
2009  
582
HIV-1 associated dementia: update on pathological mechanisms and therapeutic approaches.
[19300249] Curr Opin Neurol 22(3): 315-20 (2009)
2011  
583
Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.
[21649911] Mol Brain 4(1): 23 (2011)
2010  
584
HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities.
[20396973] J Neuroimmune Pharmacol 5(3): 294-309 (2010)
2011  
585
Proteomic analysis of HIV-infected macrophages.
[21153888] J Neuroimmune Pharmacol 6(1): 89-106 (2011)
2010  
586
Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders.
[19697136] J Neuroimmune Pharmacol 5(1): 44-62 (2010)
2010  
587
Innate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation.
[20387125] J Neuroimmune Pharmacol 5(3): 278-93 (2010)
2009  
588
Host and viral factors influencing the pathogenesis of HIV-associated neurocognitive disorders.
[19373562] J Neuroimmune Pharmacol 4(2): 175-89 (2009)
2010  
589
Neurologic presentations of AIDS.
[19932385] Neurol Clin 28(1): 253-75 (2010)
2008  
590
2004  
591
Human immunodeficiency virus infection of the brain: pitfalls in evaluating infected/affected cell populations.
[14997942] Brain Pathol 14(1): 97-108 (2004)
2010  
592
Naturally occurring variability in the envelope glycoprotein of HIV-1 and development of cell entry inhibitors.
[20166763] Biochemistry 49(11): 2359-67 (2010)
2008  
593
Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease.
[18547629] J Allergy Clin Immunol 122(1): 12-9; quiz 20-1 (2008)
2006  
594
Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade.
[17000870] J Exp Med 203(10): 2223-7 (2006)
2010  
595
When should antiretroviral therapy be started in HIV-positive persons?
[21170371] F1000 Med Rep 2(-): 81 (2010)
2002  
596
Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America.
[12081007] MMWR Recomm Rep 51(RR-8): 1-52 (2002)
2002  
597
Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.
[12027060] MMWR Recomm Rep 51(RR-7): 1-55 (2002)
2005  
598
Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis.
[16195697] MMWR Recomm Rep 54(RR-9): 1-17 (2005)
2008  
599
Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC).
[18668022] MMWR Recomm Rep 57(RR-6): 1-21; quiz CE1-4 (2008)
2004  
600
Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America.
[15841069] MMWR Recomm Rep 53(RR-15): 1-112 (2004)
2004  
601
Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America.
[15577752] MMWR Recomm Rep 53(RR-14): 1-92 (2004)
2009  
602
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America.
[19357635] MMWR Recomm Rep 58(RR-4): 1-207; quiz CE1-4 (2009)
2004  
603
GB virus type C: a beneficial infection?
[15364968] J Clin Microbiol 42(9): 3915-9 (2004)
2007  
604
HIV-1 immunopathogenesis: how good interferon turns bad.
[17112786] Clin Immunol 123(2): 121-8 (2007)
2008  
605
Chronic innate immune activation as a cause of HIV-1 immunopathogenesis.
[17916442] Clin Immunol 126(3): 235-42 (2008)
2008  
606
HIV infection in India: epidemiology, molecular epidemiology and pathogenesis.
[19208977] J Biosci 33(4): 515-25 (2008)
2008  
607
HIV and tuberculosis in India.
[19208978] J Biosci 33(4): 527-37 (2008)
2007  
608
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.
[17634242] J Virol 81(19): 10209-19 (2007)
2008  
609
Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation.
[17855541] J Virol 82(3): 1066-72 (2008)
2006  
610
The cell biology of HIV-1 and other retroviruses.
[17083721] Retrovirology 3(-): 77 (2006)
2011  
611
The utility of the new generation of humanized mice to study HIV-1 infection: transmission, prevention, pathogenesis, and treatment.
[21835012] Retrovirology 8(-): 65 (2011)
2011  
612
The role of unintegrated DNA in HIV infection.
[21722380] Retrovirology 8(-): 52 (2011)
2010  
613
Innate immunity against HIV: a priority target for HIV prevention research.
[20937128] Retrovirology 7(-): 84 (2010)
2010  
614
Revisiting HIV-1 uncoating.
[21083892] Retrovirology 7(-): 96 (2010)
2010  
615
Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection.
[20374632] Retrovirology 7(-): 30 (2010)
2010  
616
Limelight on two HIV/SIV accessory proteins in macrophage infection: is Vpx overshadowing Vpr?
[20380700] Retrovirology 7(-): 35 (2010)
2008  
617
2011  
618
HIV-1 co-receptor usage: influence on mother-to-child transmission and pediatric infection.
[21284900] J Transl Med 9 Suppl 1(-): S10 (2011)
2011  
619
HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV.
[21284901] J Transl Med 9 Suppl 1(-): S2 (2011)
2011  
620
R5X4 HIV-1 coreceptor use in primary target cells: implications for coreceptor entry blocking strategies.
[21284902] J Transl Med 9 Suppl 1(-): S3 (2011)
2011  
621
Natural anti-CCR5 antibodies in HIV-infection and -exposure.
[21284903] J Transl Med 9 Suppl 1(-): S4 (2011)
2011  
622
Clinical significance of HIV-1 coreceptor usage.
[21284904] J Transl Med 9 Suppl 1(-): S5 (2011)
2011  
623
Selective transmission of R5 HIV-1 variants: where is the gatekeeper?
[21284905] J Transl Med 9 Suppl 1(-): S6 (2011)
2011  
624
Coreceptor use in nonhuman primate models of HIV infection.
[21284906] J Transl Med 9 Suppl 1(-): S7 (2011)
2011  
625
Asymmetric HIV-1 co-receptor use and replication in CD4(+) T lymphocytes.
[21284907] J Transl Med 9 Suppl 1(-): S8 (2011)
2011  
626
Clinical use of CCR5 inhibitors in HIV and beyond.
[21284908] J Transl Med 9 Suppl 1(-): S9 (2011)
2010  
627
Roles of Vpr and Vpx in modulating the virus-host cell relationship.
[20558198] Mol Aspects Med 31(5): 398-406 (2010)
2009  
628
Prospects for antisense peptide nucleic acid (PNA) therapies for HIV.
[19534584] Expert Opin Biol Ther 9(8): 975-89 (2009)
2011  
629
The cytokine network of acute HIV infection: a promising target for vaccines and therapy to reduce viral set-point?
[21852945] PLoS Pathog 7(8): e1002055 (2011)
2010  
630
CD8+ T cell control of HIV--a known unknown.
[20126440] PLoS Pathog 6(1): e1000728 (2010)
2010  
631
Contribution of CNS cells in NeuroAIDS.
[21180461] J Pharm Bioallied Sci 2(4): 300-6 (2010)
2007  
632
Immunobiology of human imunodeficiency virus infection.
[18087078] Indian J Med Microbiol 25(4): 311-22 (2007)
2008  
633
Gynecologic issues in the HIV-infected woman.
[18954760] Infect Dis Clin North Am 22(4): 709-39, vii (2008)
2002  
634
2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.
[12090361] Infect Dis Obstet Gynecol 10(1): 3-64 (2002)
2011  
635
Safety and tolerability of antiretrovirals during pregnancy.
[21603231] Infect Dis Obstet Gynecol 2011(-): 867674 (2011)
2010  
636
Methicillin-resistant Staphylococcus aureus in HIV-infected patients.
[21694896] Infect Drug Resist 3(-): 73-86 (2010)
2009  
637
Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.
[19786840] Hum Vaccin 5(12): 867-71 (2009)
2010  
638
Mechanisms of HIV-associated lymphocyte apoptosis: 2010.
[21368875] Cell Death Dis 1(-): e99 (2010)
2011  
639
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons.
[21617825] New Microbiol 34(2): 109-46 (2011)
2010  
640
The role of HIV-DNA testing in clinical practice.
[20402409] New Microbiol 33(1): 1-11 (2010)
2007  
641
Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.
[17619250] New Microbiol 30(2): 79-88 (2007)
2008  
642
Bone alterations during HIV infection.
[18623979] New Microbiol 31(2): 155-64 (2008)
2010  
643
Efavirenz in the therapy of HIV infection.
[20001610] Expert Opin Drug Metab Toxicol 6(1): 95-103 (2010)
2008  
644
Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors.
[18372072] Virus Res 134(1-2): 147-56 (2008)
2008  
645
HIV infection and the gastrointestinal immune system.
[19079157] Mucosal Immunol 1(1): 23-30 (2008)
2010  
646
Liver disease in the HIV-infected individual.
[20851211] Clin Gastroenterol Hepatol 8(12): 1002-12 (2010)
2011  
647
Targeting the protein-protein interactions of the HIV lifecycle.
[21152581] Chem Soc Rev 40(3): 1337-46 (2011)
2010  
648
Integrase inhibitors in the treatment of HIV-1 infection.
[20852268] J Antimicrob Chemother 65(12): 2485-8 (2010)
2010  
649
Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes.
[20651298] J Leukoc Biol 88(6): 1119-30 (2010)
2010  
650
HIV neuropathogenesis: a tight rope walk of innate immunity.
[20354805] J Neuroimmune Pharmacol 5(4): 489-95 (2010)
2010  
651
Functional contributions of carbohydrate on AIDS virus glycoprotein.
[21165339] Yale J Biol Med 83(4): 201-8 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Aids.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Aids.php on line 92